Berking Theranostics

Our RadioNab® technology represents the fusion of biological precision and radiological power. In 2017, Dr. Alejandro Rojas-Fernandez founded an advanced nanoantibodies platform targeting the Hantavirus Andes strain in Chile. His team identified three nanobody superfamilies to neutralize this unique virus transmitted by specific Andean rodents. Amidst the global pandemic, Dr. Rojas’s collaborative efforts with Australian researchers led to substantial breakthroughs, discovering potent nanobodies against the threatening Nipah and Hendra viruses, thus broadening the scope of their impactful virology research. Founded in 2023 in Hamburg, Berking Theranostics was established with the vision to revolutionize cancer care through precision medicine. Inspired by the unique properties of alpaca-derived nanobodies, we have developed a pioneering platform that redefines Theranostics.